Despite advances in our understanding of the pathophysiology of many cardiovascular
diseases (CVDs) and expansion of available therapies, the global burden of CVD …

It is now about 20 years since the first case of a gain-of-function mutation involving the as-yet-
unknown actor in cholesterol homeostasis, proprotein convertase subtilisin/kexin type 9 …

PCSK9 degrades low-density lipoprotein cholesterol (LDL) receptors and subsequently
increases serum LDL cholesterol. Clinical trials show that inhibition of PCSK9 efficiently …

Lowering blood cholesterol levels efficiently reduces the risk of developing atherosclerotic
cardiovascular disease (ASCVD), including coronary artery disease (CAD), which is the …

The relevance of PCSK9 in atherosclerosis progression is demonstrated by the benefits
observed in patients that have followed PCSK9-targeted therapies. The impact of these …

The function of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), a novel plasma
protein, has mainly been involved in cholesterol metabolism in the liver, while, more …

Aims Proprotein convertase subtilisin/kexin type 9 (PCSK9) has been shown to influence
macrophage biology and modulate atherogenesis. We conducted this study to examine the …

There is increasing evidence that low-density lipoprotein (LDL) cholesterol plays a role in
the pathology of OA. Specifically, oxidized LDL (oxLDL), which has been shown to play an …

Disturbances in lipid metabolism are among the most important risk factors for
atherosclerotic cardiovascular disease. Proprotein convertase subtilisin/kexin type 9 …

Chronic kidney disease (CKD) is a health problem that is constantly growing. This disease
presents a diverse symptomatology that implies complex therapeutic management. One of …